Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ReShape Lifesciences Inc RSLS

Healthcare Medical Devices
ReShape Lifesciences Inc. is a weight-loss solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease throughout the care continuum. Its portfolio includes Lap-Band system, which provides minimally invasive, long-term treatment of obesity and is a safer surgical alternative to more invasive surgical stapling... see more

Recent & Breaking News (NDAQ:RSLS)

ReShape Lifesciences® Enters into Warrant Exercise Transaction for $1.2 Million in Gross Proceeds

GlobeNewswire 8 days ago

ReShape Lifesciences® Reports Third Quarter Ended September 30, 2023 Financial Results and 2024 Cost Reduction Plan

GlobeNewswire November 8, 2023

ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update

GlobeNewswire November 6, 2023

ReShape Lifesciences® Announces Pricing of $3.0 Million Public Offering

GlobeNewswire September 29, 2023

ReShape Lifesciences® Announces Participation in the LD Micro Main Event XVI

GlobeNewswire September 22, 2023

ReShape Lifesciences® Signs Exclusive License Agreement With Biorad Medisys for Obalon® Gastric Balloon System

GlobeNewswire September 21, 2023

ReShape Lifesciences® Significantly Strengthens Patent Portfolio Related to its Obalon® Balloon System

GlobeNewswire September 19, 2023

ReShape Lifesciences® Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation(TM) Device

GlobeNewswire September 14, 2023

ReShape Lifesciences® Reports Second Quarter Ended June 30, 2023 Financial Results and Provides Corporate Update

GlobeNewswire August 7, 2023

ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2023 and Provide Corporate Update

GlobeNewswire August 3, 2023

ReShape Lifesciences® Signs Preferred Partner Agreement With Hive Medical for Lead Optimization Software

GlobeNewswire June 29, 2023

ReShape Lifesciences® Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation(TM) Device at the ASMBS 2023 Annual Meeting

GlobeNewswire June 28, 2023

ReShape Lifesciences® Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0

GlobeNewswire June 26, 2023

ReShape Lifesciences® to Participate in Investor and Industry Conferences in June

GlobeNewswire June 14, 2023

ReShape Lifesciences® Reports First Quarter Ended March 31, 2023 Financial Results and Provides Corporate Update

GlobeNewswire May 15, 2023

ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2023 and Provide Corporate Update

GlobeNewswire May 11, 2023

ReShape Lifesciences® to Present Data on its Proprietary Diabetes Bloc-Stim Neuromodulation(TM) Device at the Keystone Symposia on Type 2 Diabetes

GlobeNewswire April 27, 2023

ReShape Lifesciences® Reports Year Ended December 31, 2022 Financial Results and Provides Corporate Update

GlobeNewswire April 25, 2023

ReShape Lifesciences Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market

GlobeNewswire April 20, 2023

ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to its Obalon® Balloon System

GlobeNewswire April 11, 2023